EXEL - EXELIXIS, INC.
41.28
-0.410 -0.993%
Share volume: 3,438,511
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$41.69
-0.41
-0.01%
View ratios
| Fiscal Date | 03-29-2024 | 06-28-2024 | 09-27-2024 | 01-03-2025 | 04-04-2025 | 07-04-2025 | 10-03-2025 | 01-02-2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 04-30-2024 | 08-06-2024 | 10-29-2024 | 02-11-2025 | 05-13-2025 | 07-28-2025 | 11-04-2025 | 02-10-2026 | |
| Assets | |||||||||
| Total Assets | 2.804 B | 2.773 B | 2.960 B | 2.948 B | 2.837 B | 2.678 B | 2.824 B | 2.844 B | |
| Current Assets | 1.292 B | 1.477 B | 1.550 B | 1.468 B | 1.397 B | 1.181 B | 1.402 B | 1.443 B | |
| Inventories | 21.106 M | 20.614 M | 21.013 M | 22.388 M | 24.853 M | 23.483 M | 27.402 M | 21.686 M | |
| Other Current Assets | 67.490 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 67.490 M | 803.540 M | 930.815 M | 893.902 M | 847.564 M | 626.665 M | 612.235 M | 576.603 M | |
| Total Receivables | 240.577 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 963.256 M | 198.459 M | 258.346 M | 217.374 M | 183.752 M | 164.433 M | 376.300 M | 482.488 M | |
| Total Non-current Assets | 1.511 B | 432.305 M | 523.421 M | 637.291 M | 619.441 M | 594.652 M | 578.287 M | 603.603 M | |
| Property Plant Equipment | 127.222 M | 130.210 M | 124.414 M | 119.391 M | 115.030 M | 110.314 M | 104.748 M | 98.960 M | |
| Other Assets | 329.278 M | 1.165 B | 1.286 B | 1.361 B | 1.326 B | 1.387 B | 1.317 B | 1.302 B | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 63.684 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.804 B | 2.773 B | 2.960 B | 2.948 B | 2.837 B | 2.678 B | 2.824 B | 2.844 B | |
| Total liabilities | 675.744 M | 653.387 M | 684.857 M | 703.487 M | 706.223 M | 644.545 M | 662.847 M | 683.104 M | |
| Total current liabilities | 373.010 M | 345.703 M | 394.346 M | 403.769 M | 399.102 M | 336.111 M | 373.777 M | 405.644 M | |
| Accounts Payable | 26.069 M | 28.676 M | 59.309 M | 38.191 M | 42.840 M | 25.821 M | 25.348 M | 29.623 M | |
| Other liabilities | 101.268 M | 307.684 M | 290.511 M | 299.718 M | 307.121 M | 308.434 M | 289.070 M | 277.460 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 101.268 M | 307.684 M | 290.511 M | 299.718 M | 307.121 M | 308.434 M | 289.070 M | 277.460 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 2.128 B | 2.120 B | 2.275 B | 2.244 B | 2.131 B | 2.034 B | 2.161 B | 2.161 B | |
| Common stock | 300.757 M | 2.325 B | 2.362 B | 2.344 B | 2.292 B | 2.252 B | 2.263 B | 2.235 B | |
| Retained earnings | -258.948 M | -199.972 M | -90.293 M | -98.647 M | -163.294 M | -219.539 M | -106.061 M | -76.830 M |